News for Biogen Inc. (BIIB)

Sanofi has agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the company aims to expand the company's reach in rare immunological diseases. Blueprint Medicines shares were trading more than 26% higher ahead of US market open.

**media[618818]**

Mizuho has adjusted its price target for Biogen (BIIB), bringing it down from $207 to $169 while maintaining an Outperform rating. This revision follows an upda

On May 5, 2025, JP Morgan's analyst Chris Schott made a noteworthy update on Biogen (BIIB), maintaining a 'Neutral' rating while lowering the price target. The

JPMorgan has revised its price target for Biogen (BIIB), reducing it from $185 to $175 while maintaining a Neutral rating on the stock. This adjustment comes af

Biogen Inc. sees significant revenue growth from new products, contributing 45% of total revenue. Analysts predict substantial upside for Biogen stock w

Discover key insights from Biogen's Q1 2025 earnings call, highlighting LEQEMBI's growth, product launches, and a strong pipeline driving portfolio...

Biogen Inc. (NASDAQ:BIIB) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ETCompany ParticipantsTim Power - Head, Investor RelationsChris Viehbacher -...

Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Biogen's revenue sees a 6.1% boost, driven by strategic product positioning. Analysts predict substantial potential upside with a high price target of $

Key Takeaways: Biogen Inc. (BIIB) posts strong quarterly results with non-GAAP EPS of $3.02. Analyst consensus targets an average price increase of nearl

PR NewswireDUBLIN, May 1, 2025 ”” First Quarter Revenues of $306.5 Million ”””” GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Sha

The following slide deck was published by Biogen Inc.

Biogen (BIIB) has revised its financial guidance for the full year 2025. This update incorporates a $165 million upfront payment related to a transaction with S

Biogen (BIIB) delivered earnings and revenue surprises of -7.36% and 8.91%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Investors are closely watching Biogen (BIIB) as the company prepares to announce its earnings before the market opens tomorrow. Financial experts have set the c

Biogen (BIIB) is set to announce its Q1 financials with expected declines in both EPS and revenue. Analysts anticipate a significant upside potential, m

Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. ”œWe delivered s

Truist has revised its price target for Biogen (BIIB), decreasing it from $210 to $199 while maintaining a Buy rating. The update comes as the firm adjusts its